+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Lyme Disease - Pipeline Review, H1 2020

  • ID: 4986878
  • Drug Pipelines
  • January 2020
  • Region: Global
  • 59 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Abzyme Therapeutics LLC
  • Agile Sciences Inc
  • Ixodes AG
  • L2 Diagnostics LLC
  • Valneva SE
  • MORE
Lyme Disease - Pipeline Review, H1 2020

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Lyme Disease - Pipeline Review, H1 2020, provides an overview of the Lyme Disease (Infectious Disease) pipeline landscape.

Lyme disease is a bacterial infection transmitted by a tick. Lyme disease is caused by the bacterium Borrelia burgdorferi. Symptoms include rash, fever, chills, fatigue, body aches and headache. Risk factors include age, gender and geographic locations. Treatment includes antibiotics.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Lyme Disease - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Lyme Disease (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Lyme Disease (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Lyme Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 5 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Lyme Disease (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Lyme Disease (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Lyme Disease (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Lyme Disease (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Lyme Disease (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Lyme Disease (Infectious Disease)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Lyme Disease (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Lyme Disease (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Abzyme Therapeutics LLC
  • Agile Sciences Inc
  • Ixodes AG
  • L2 Diagnostics LLC
  • Valneva SE
  • MORE
  • Introduction
  • Report Coverage
  • Lyme Disease - Overview
  • Lyme Disease - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Lyme Disease - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Lyme Disease - Companies Involved in Therapeutics Development
  • Abzyme Therapeutics LLC
  • Agile Sciences Inc
  • Flightpath BioSciences Inc
  • Inovio Pharmaceuticals Inc
  • Ixodes AG
  • L2 Diagnostics LLC
  • NovoBiotic Pharmaceuticals LLC
  • Valneva SE
  • Lyme Disease - Drug Profiles
  • azithromycin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Lyme Disease - Dormant Projects
  • Lyme Disease - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
List of Tables
  • Number of Products under Development for Lyme Disease, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Lyme Disease - Pipeline by Abzyme Therapeutics LLC, H1 2020
  • Lyme Disease - Pipeline by Agile Sciences Inc, H1 2020
  • Lyme Disease - Pipeline by Flightpath BioSciences Inc, H1 2020
  • Lyme Disease - Pipeline by Inovio Pharmaceuticals Inc, H1 2020
  • Lyme Disease - Pipeline by Ixodes AG, H1 2020
  • Lyme Disease - Pipeline by L2 Diagnostics LLC, H1 2020
  • Lyme Disease - Pipeline by NovoBiotic Pharmaceuticals LLC, H1 2020
  • Lyme Disease - Pipeline by Valneva SE, H1 2020
  • Lyme Disease - Dormant Projects, H1 2020
List of Figures
  • Number of Products under Development for Lyme Disease, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Abzyme Therapeutics LLC
  • Agile Sciences Inc
  • Flightpath BioSciences Inc
  • Inovio Pharmaceuticals Inc
  • Ixodes AG
  • L2 Diagnostics LLC
  • NovoBiotic Pharmaceuticals LLC
  • Valneva SE
Note: Product cover images may vary from those shown
Adroll
adroll